Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02235558 · ClinicalTrials.gov registry record · Phase 1
Superselective Administration of VErapamil During Recanalization in Acute Ischemic Stroke
A Phase 1 study, sponsored by Justin Fraser.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT02235558 is a Phase 1 study that has completed, run by Justin Fraser. The registered enrollment target is 11 participants.
The verdict
NCT02235558, a Phase 1 study, has completed, sponsored by Justin Fraser.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether super-selective intra-arterial administration of verapamil immediately following successful intra-arterial thrombolysis is safe as a potential neuroprotective agent. Standard procedures are cerebral angiography and intra-arterial thrombolysis (intra-arterial administration of tPA and/or mechanical thrombectomy). Experimental procedure is superselective injection of verapamil intra-arterially.
Interventions
- DRUG Verapamil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2013-02-01 |
| Est. Completion | 2016-03-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02235558
The ClinicalTrials.gov registry entry for NCT02235558 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Justin Fraser, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Verapamil is the first listed.
NCT02235558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02235558 about?
NCT02235558 is a clinical study titled "Superselective Administration of VErapamil During Recanalization in Acute Ischemic Stroke". The purpose of this study is to determine whether super-selective intra-arterial administration of verapamil immediately following successful intra-arterial thrombolysis is safe as a potential neuroprotective agent. Standard procedures are cerebral angiography and intra-arterial thrombolysis (intra-...
What is the current status of trial NCT02235558?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2013-02-01. Estimated completion is 2016-03-21.
What interventions are being tested in trial NCT02235558?
The interventions under investigation include: Verapamil (DRUG).
Who is sponsoring clinical trial NCT02235558?
This trial is sponsored by Justin Fraser, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.